Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan Swindells

Showing results (121-130 of 170) with videos related to

Pageof 17
Sort By:
BMC Health Services Research|March 21, 2021
Multi-level considerations for optimal implementation of long-acting injectable antiretroviral therapy to treat people living with HIV: perspectives of health care providers participating in phase 3 trialsAndrea Mantsios, Miranda Murray, Tahilin S Karver, et al.
Culture, Health & Sexuality|May 22, 2020
"I feel empowered": women's perspectives on and experiences with long-acting injectable antiretroviral therapy in the USA and SpainAndrea Mantsios, Miranda Murray, Tahilin S Karver, et al.
The Journal of Infectious Diseases|February 5, 2009
Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy: final 48-week clinical and virologic outcomesTimothy J Wilkin, John E McKinnon, A Gregory DiRienzo, et al.
The New England Journal of Medicine|May 16, 2008
Class-sparing regimens for initial treatment of HIV-1 infectionSharon A Riddler, Richard Haubrich, A Gregory DiRienzo, et al.
American Journal of Respiratory and Critical Care Medicine|August 17, 2021
A Semimechanistic Model of the Bactericidal Activity of High-Dose Isoniazid against Multidrug-Resistant Tuberculosis: Results from a Randomized Clinical TrialKamunkhwala Gausi, Elisa H Ignatius, Xin Sun, et al.
Open Forum Infectious Diseases|January 5, 2026
Monocyte Activation in People With HIV and Tuberculosis Coinfection and Effect of Tuberculosis Preventive Therapy: An Analysis of the ACTG A5279/BRIEF TB TrialMoises A Huaman, Manuel G Feria, Michelle A Kendall, et al.
The Journal of Antimicrobial Chemotherapy|June 9, 2022
Pharmacokinetics of standard versus high-dose isoniazid for treatment of multidrug-resistant tuberculosisKamunkhwala Gausi, Maxwell Chirehwa, Elisa H Ignatius, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 27, 2021
Resistance to Mycobacterium tuberculosis Infection Among Household Contacts: A Multinational StudyDavit Baliashvili, Neel R Gandhi, Soyeon Kim, et al.
BMC Infectious Diseases|February 25, 2021
Drug susceptibility patterns of Mycobacterium tuberculosis from adults with multidrug-resistant tuberculosis and implications for a household contact preventive therapy trialAnne-Marie Demers, Soyeon Kim, Sara McCallum, et al.
Journal of Viral Hepatitis|March 28, 2024
Preferences and feasibility of long-acting technologies for treatment of hepatitis C virus in low- and middle-income countries: A survey of providers and policymakersNeil Gupta, Susan Swindells, Kimberly K Scarsi, et al.
Pageof 17

Showing results (121-130 of 170) with videos related to

Sort By:
Pageof 17
BMC Health Services Research|March 21, 2021
Multi-level considerations for optimal implementation of long-acting injectable antiretroviral therapy to treat people living with HIV: perspectives of health care providers participating in phase 3 trialsAndrea Mantsios, Miranda Murray, Tahilin S Karver, et al.
Culture, Health & Sexuality|May 22, 2020
"I feel empowered": women's perspectives on and experiences with long-acting injectable antiretroviral therapy in the USA and SpainAndrea Mantsios, Miranda Murray, Tahilin S Karver, et al.
The Journal of Infectious Diseases|February 5, 2009
Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy: final 48-week clinical and virologic outcomesTimothy J Wilkin, John E McKinnon, A Gregory DiRienzo, et al.
The New England Journal of Medicine|May 16, 2008
Class-sparing regimens for initial treatment of HIV-1 infectionSharon A Riddler, Richard Haubrich, A Gregory DiRienzo, et al.
American Journal of Respiratory and Critical Care Medicine|August 17, 2021
A Semimechanistic Model of the Bactericidal Activity of High-Dose Isoniazid against Multidrug-Resistant Tuberculosis: Results from a Randomized Clinical TrialKamunkhwala Gausi, Elisa H Ignatius, Xin Sun, et al.
Open Forum Infectious Diseases|January 5, 2026
Monocyte Activation in People With HIV and Tuberculosis Coinfection and Effect of Tuberculosis Preventive Therapy: An Analysis of the ACTG A5279/BRIEF TB TrialMoises A Huaman, Manuel G Feria, Michelle A Kendall, et al.
The Journal of Antimicrobial Chemotherapy|June 9, 2022
Pharmacokinetics of standard versus high-dose isoniazid for treatment of multidrug-resistant tuberculosisKamunkhwala Gausi, Maxwell Chirehwa, Elisa H Ignatius, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 27, 2021
Resistance to Mycobacterium tuberculosis Infection Among Household Contacts: A Multinational StudyDavit Baliashvili, Neel R Gandhi, Soyeon Kim, et al.
BMC Infectious Diseases|February 25, 2021
Drug susceptibility patterns of Mycobacterium tuberculosis from adults with multidrug-resistant tuberculosis and implications for a household contact preventive therapy trialAnne-Marie Demers, Soyeon Kim, Sara McCallum, et al.
Journal of Viral Hepatitis|March 28, 2024
Preferences and feasibility of long-acting technologies for treatment of hepatitis C virus in low- and middle-income countries: A survey of providers and policymakersNeil Gupta, Susan Swindells, Kimberly K Scarsi, et al.
Pageof 17